功能化纳米粒子:对有效管理阿尔茨海默病的有希望的方法
Subhasri Bogadi1, Mahendran Bhaskaran2, Vishnuvardh Ravichandran3
1Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research, OotyNilgiris, Tamil Nadu, India.
Molecular neurobiology
|April 15, 2025
概括
功能化纳米粒子为治疗阿尔茨海默病 (AD) 提供了一个有希望的新途径. 这些纳米颗粒可以向粉样β斑块和陶聚合物,潜在地改善认知功能并为患者提供希望.
科学领域:
- 神经科学是一个神经科学.
- 生物技术是生物技术.
- 材料科学 材料科学 材料科学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,其特点是记忆力丧失和认知能力下降.
- 随着AD患病率的上升,需要新的治疗策略,纳米技术成为一个有前途的领域.
- 阿尔茨海默病的主要病理特征包括粉样β斑块和蛋白聚合物.
研究的目的:
- 审查最近在合成,设计和应用功能化纳米颗粒 (NP) 的阿尔茨海默病治疗的进展.
- 探索功能化NP在神经保护,减少粉样β聚合和增强血脑屏障透方面的潜力.
- 讨论NP在疾病修饰,症状缓解以及AD治疗的未来方向中的作用.
主要方法:
- 关于功能化纳米粒子合成和AD的设计的当前文献的审查.
- 对NP功能化技术的分析,包括表面修饰和生物结合.
- 在AD模型中检查NP有效性和安全性的临床前和临床研究.
主要成果:
- 功能化的NP显示出向药物输送的潜力,并在AD治疗中提高了生物相容性.
- 在神经保护,减少粉样β聚合和穿越血脑屏障方面,NP显示出有前途.
- 临床前和临床研究强调了NP在疾病修饰和症状管理方面的治疗潜力.
结论:
- 功能化纳米颗粒代表了一种多模式策略,在阿尔茨海默病治疗方面具有重大前景.
- 纳米技术为阿兹海默症患者改善生活质量,早期诊断和有效的疾病管理提供了希望.
- 对NP毒性和安全性的进一步研究对于在AD治疗中推进其临床应用至关重要.
相关概念视频
Alzheimer's Disease: Treatment
128
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
128
Alzheimer's Disease: Overview
328
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
328
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
85
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
85


